These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 31727344)

  • 41. Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors.
    Fiala O; Sorejs O; Sustr J; Kucera R; Topolcan O; Finek J
    Anticancer Res; 2020 Mar; 40(3):1219-1227. PubMed ID: 32132018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.
    Tanios GE; Doley PB; Munker R
    Eur J Haematol; 2019 Feb; 102(2):157-162. PubMed ID: 30347480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.
    Kanz BA; Pollack MH; Johnpulle R; Puzanov I; Horn L; Morgans A; Sosman JA; Rapisuwon S; Conry RM; Eroglu Z; Johnson DB
    J Immunother Cancer; 2016; 4():60. PubMed ID: 27777770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.
    Ruggiero R; Balzano N; Di Napoli R; Fraenza F; Pentella C; Riccardi C; Donniacuo M; Tesorone M; Danesi R; Del Re M; Rossi F; Capuano A
    Front Immunol; 2023; 14():1134436. PubMed ID: 37006303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of Immunotherapy-Related Toxicities, Version 1.2019.
    Thompson JA; Schneider BJ; Brahmer J; Andrews S; Armand P; Bhatia S; Budde LE; Costa L; Davies M; Dunnington D; Ernstoff MS; Frigault M; Hoffner B; Hoimes CJ; Lacouture M; Locke F; Lunning M; Mohindra NA; Naidoo J; Olszanski AJ; Oluwole O; Patel SP; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wahidi M; Wang Y; Johnson-Chilla A; Scavone JL
    J Natl Compr Canc Netw; 2019 Mar; 17(3):255-289. PubMed ID: 30865922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
    Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
    Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
    Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
    Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review.
    Abdihamid O; Omar A; Rugambwa T
    Ecancermedicalscience; 2021; 15():1314. PubMed ID: 35047065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
    Nadeau BA; Fecher LA; Owens SR; Razumilava N
    Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of immune related adverse events induced by immune checkpoint inhibition.
    Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
    Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
    Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
    Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
    Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
    Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.